Tyrosine kinase inhibitors(TKIs) have improved the overall survival of patients with gastrointestinalstromaltumors(GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To...
详细信息
Tyrosine kinase inhibitors(TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors(GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or consensus has been published on the TKI-associated adverse reactions. Therefore, the chinese society of surgeons for gastrointestinal stromal tumor of the chinese medical doctor association organized an expert panel discussion involving representatives from gastrointestinal surgery, medical oncology, cardiology, dermatology, nephrology, endocrinology, and ophthalmology to consider the systemic clinical symptoms, molecular and cellular mechanisms, and treatment recommendations of GISTs. Here, we present the resultant evidence-and experience-based consensus to guide the management of TKI-associated side events in clinical practice.
暂无评论